Table 1.
IC50 for selected phosphane gold(I) compounds on breast cancer cell lines. The active compounds are quoted mentioning their coordination chemical environment at the gold(I) center while the structures are shown in Scheme 2 labeled with the relative entries.
| P-Au-X (X = P, C, N, S) | MCF7 | MDA-MB-231 | Ref | Entries |
|---|---|---|---|---|
| P-Au-P (1,2-bis(diphenylphosphane) | nd | 0.76 ± 0.27 (72 h) | [27] | 1 |
| P-Au-N (hypoxanthine) | 12.40 ± 1.07 (24 h) | nd | [28] | 2 |
| P-Au-S (thio-derivatives) | 1.14 ± 0.08 (48 h) | nd | [29] | 3 |
| P-Au-Cl (chiral diphosphanes) | nd | 0.44 ± 0.093 (17 h) | [30] | 4 |
| P-Au-S (PCy3, mercaptobenzoate) | 7.26 (24 h) | nd | [31] * | 5 |
| P-Au-S (thiocarbammate) | 16.00 ± 0.83 (72 h) | nd | [32] | 6 |
| P-Au-C(alkynyl) | nd | 51.78 ± 0.69 (6 h) | [33] | 7 |
| P-Au-S (thiosugar) | 2.30 (48 h) | nd | [34] | 8 |
| P-Au-S (thiourea derivatives) | 2.35 ± 0.39 | 2.75 ± 0.40 (48 h) | [35] | 9 |
| P-Au-P (aminephosphane) | 51.73 ± 2.25 | nd | [37] | 10 |
| P-Au-N (imidazole) | nd | 14.83 ± 1.05 (24 h) | [38] | 11 |
| P-Au-C (alkynyl) | 5.5 ± 0.7 (24 h) | 9.7 ± 2.5 (24 h) | [39] | 12 |
| P-Au-C (alkynyl) | 1.25 ± 0.05 (72 h) | 1.97 ± 0.10 (72 h) | [40] | 13 |
| P-Au-C (erlotinib) | 2.62 ± 0.17 | 1.64 ± 0.13 | [41] | 14 |
| P-Au-S (thiazoles) | 5.38 ± 0.13 | nd | [42] ^ | 15 |
| Auranofin (in combination with Vitamin C) | nd | 0.6 ± 0.03 | [20] | |
| Auranofin | 2.00 ± 0.05 | 1.54 ± 0.12 | [43] ° | |
| Cisplatin | 6.35 ± 1.65 | [27] |